title: [The anti-androgen flutamide in the treatment of prostatic hyperplasia].
abstract: The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide. Half of the patients were treated with 500 mg, the another part with 750 mg flutamide for three months, and after 3 months brake again for 3 months. The decrease of the residual urine and an increase of the flow were observed. The subjective parameters were improved, too. In some patients side effects (gynecomastia, loss of appetite and potency) were observed. There was no different in the effect of the two doses.
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005485:Flutamide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D005485:Flutamide
vernacular_title: Antiandrogén flutamid terápia a prostata hyperplasia kezelésére.